Y Intercept Hong Kong Ltd Increases Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Y Intercept Hong Kong Ltd grew its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 14.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,090 shares of the biotechnology company’s stock after purchasing an additional 1,143 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Sarepta Therapeutics were worth $1,105,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Manchester Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 156 shares during the period. Sunbelt Securities Inc. lifted its position in Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares in the last quarter. Huntington National Bank grew its holdings in Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 175 shares during the period. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Sarepta Therapeutics in the fourth quarter worth about $36,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $106.86 on Thursday. Sarepta Therapeutics, Inc. has a 52-week low of $101.15 and a 52-week high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The firm’s fifty day moving average is $116.47 and its 200 day moving average is $122.90. The company has a market cap of $10.21 billion, a price-to-earnings ratio of 85.49 and a beta of 0.75.

Insider Activity

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on SRPT. Piper Sandler lowered their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. HC Wainwright reiterated a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 13th. Guggenheim raised their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $176.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.